Aim: Recently we have observed differences in the ability of metformin and AICAR to repress glucose production from hepatocytes using 8CPT-cAMP. Previous results indicate that, in addition to activating protein kinase A, 8CPT-modified cAMP analogues suppress the nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter ENT1. We aimed to exploit 8CPT-cAMP, 8CPT-2-Methyl-O-cAMP and NBMPR, which is highly selective for a highaffinity binding-site on ENT1, to investigate the role of ENT1 in the liver-specific glucoselowering properties of AICAR and metformin.
The hyperglycaemic effect of the glucagon/cAMP/PKA signalling pathway on liver cells has been studied using a number of different cAMP analogues, in combination with dexamethasone, to stimulate cAMP/PKA. [3] [4] [5] The cAMP analogue dibutyryl cAMP (bucladesine, dbcAMP), a cell-permeable stabilized cAMP mimic that also inhibits phosphodiesterase (PDE) activity, is commonly used. 6,7 Treatment of cells with db-cAMP causes a significant stimulation of PEPCK and G6-Pase expression, which is inhibited by the addition of insulin in a dose-dependent manner. 8-10 8-(4-chlorophenylthio)cAMP (8CPT-cAMP), like db-cAMP, is a membrane-permeable cAMP analogue that stimulates PEPCK and G-6-Pase. 4 ,11 It tends to be more potent than cAMP, is more resistant to phosphodiesterase-dependent hydrolysis and acts as a PDE inhibitor.
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Studies using cAMP analogues have shown previously that the T2D drug metformin and 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) repress cAMP-stimulated hepatocyte glucose production (HGP). [13] [14] [15] Inside cells, AICAR is phosphorylated by adenosine kinase to form ZMP, which then mimics AMP to activate AMPK. 16 Metformin and AICAR are both activators of AMPK; however, earlier studies, including some carried out in mice where the catalytic subunits of AMPK are genetically ablated, demonstrated that suppression of HGP occurs independently of AMPK activation. [13] [14] [15] 17, 18 Metformin is transported across hepatocyte cell membranes, at least in part, by an organic cation transporter (OCT) family of transporters. [18] [19] [20] Previous studies using siRNA determined that AICAR is transported by ENT1
and CNT3 into human macrophages, 21 whereas AICAR uptake into hepatocytes and its role concerning HGP is less clear. Initiating the current investigation, we observed that HGP was highly resistant to inhibition by AICAR only when 8CPT-modified cAMP analogues were used to stimulate HGP. In contrast, repression of HGP by metformin was unaffected. 8CPT-modified cAMP analogues have been shown previously to inhibit the equilibrative nucleoside transporter (ENT1), which is expressed in the liver 22 and transports nucleosides across the plasma membrane, depending on the nucleoside concentration gradient. 23 The inhibitory effect of 8CPT-modified cAMP analogues on AICAR action prompted us to investigate the role of ENT1 in metformin and AICARinduced regulation of HGP using NBMPR, a highly selective ENT1
inhibitor. 24 Our study indicates that suppression of ENT1 activity is sufficient to induce HGP. Moreover, the effects of AICAR, but not of metformin, on HGP are sensitive to ENT1 inhibition. These data highlight direct and indirect roles of ENT1 in modulating HGP.
| MATERIALS AND METHODS

| Materials
AICAR and 4-Nitrobenzylthioinosine (NBMPR) were purchased from Tocris (Abingdon, UK). Dibutyryl cAMP, uridine and metformin were purchased from Sigma (Dorset, UK Media was harvested for measurement of glucose and hepatocytes were lysed. The amount of glucose present in the media was measured using a GAGO glucose oxidase kit (Sigma). Glucose assays were performed in a 96-well plate format. 50 μL of cell culture media was incubated with 100 μL of glucose oxidase/peroxidase assay reagent for 30 minutes at 37 C before the reaction was stopped by addition of 100 μL 12 N H 2 SO 4 . Absorbance was measured at 405 nm and the amount of glucose present was determined using a glucose standard curve generated in the same assay. The final glucose concentration was normalized to total protein content per well and data are presented as mg HGP per μg protein.
| Cell lysis and western blotting
Cells were lysed in buffer containing Tris-HCl (50 mM; pH 7.4), NaF 
| Uridine uptake assay
Primary mouse hepatocytes were incubated overnight in M199 media as described above. Cells were washed once in uridine uptake buffer 
| Liquid chromatography-mass spectrometry (LC-MS) analysis
Samples of culture media were transferred into 300 μL micro-vials and which it was serially diluted in culture media to provide calibration standard curves. Extracted ion chromatograms for AICAR were generated within Xcalibur Qual Browser software; peak areas were extracted applying the GENESIS peak detection algorithm and raw extracted peak areas were transferred to Microsoft Excel.
| Statistics
All statistical analyses were performed using GraphPad Prism version 6.0. Mean glucose values were taken from each experiment, and in one experiment were normalized to control, which was set at 100% to account for variability among different hepatocyte preparations. HGP and western blotting data were analysed by ANOVA. For the uridine uptake assay, data were expressed as percentage of control uptake and were analysed by one sample t-test, with control set to 100%. although both drugs activate AMPK. [13] [14] [15] 17, 18 In the current study, we used AMPK activation purely as a marker of drug entry into the cell. 8CPT-cAMP prevented increases in phosphorylation of acetyl CoA carboxylase (ACC) and AMPK by AICAR, but not by metformin ( Figure 1B,D) , indicating that activation of the AMPK signalling pathway by AICAR was selectively blocked by 8CPT-cAMP.
| Inhibition of AICAR's effects depends on the 8CPT moiety of 8CPT-cAMP
We investigated the ability of AICAR to suppress HGP in the presence of db-cAMP and glucagon to induce endogenous cAMP. In contrast to 8CPT-cAMP, AICAR significantly repressed HGP in the presence of db-cAMP (100 μM) ( Figure 2A ) and glucagon (100 nM) ( Figure 2B ). In addition, the effects of AICAR on AMPK and ACC phosphorylation
were not modified by db-cAMP and glucagon ( Figure 2C ,E). AICAR also suppressed HGP induced by the adenylate cyclase activator forskolin (100 μM) ( Figure S1 ). To determine whether other 8CPT-modified cAMP analogues inhibit the effect of AICAR on HGP and AMPK signalling, we utilized 8CPT-2MeO-cAMP. We incubated primary mouse hepatocytes with 8CPT-2MeO-cAMP and found that, similar to 8-CPT-cAMP, 8CPT-2MeO-cAMP blocked repression of HGP by AICAR ( Figure 3A) . When the effects of 8CPT-2MeO-cAMP on AMPK and ACC phosphorylation were studied, we found that, like 8CPT-cAMP, 8CPT-2MeO-cAMP selectively inhibited AICAR's, but not metformin's ability to stimulate AMPK signalling ( Figure 3B,F) . 
-+ -+ -+ -+ ------+ + ------+ +
FIGURE 1 8CPT-cAMP inhibits the ability of AICAR, but not of metformin, to suppress HGP in primary hepatocytes. A, HGP was measured from primary mouse hepatocytes after 8 hours of incubation, with or without 8CPT-cAMP (100 μM), in the presence or absence of metformin (Met) (250 μM) or AICAR (250 μM). B, Representative immunoblots of pThr172 AMPK and pSer79 ACC from primary hepatocytes treated with metformin (250 μM), AICAR (250 μM) AE 8CPT-cAMP (100 μM). C, D Densitometric analysis of phosphorylation of ACC (C) and AMPK (D), expressed as fold change of control (n = 3). All data are expressed as mean AE SEM and were analysed by ANOVA (*P < 0.05; **P < 0.01; ***P < 0.001). Abbreviation: Con, control
| AICAR uptake into hepatocytes is mediated by equilibrative nucleoside transporter 1 (ENT1)
Previous studies have shown that 8-CPT-modified cAMP analogues are potent inhibitors of the equilibrative nucleoside transporter 1 (ENT1), 23 which, in brain slices, was previously found to mediate AICAR uptake. 27 This led us to test whether AICAR uptake into hepatocytes may be blocked by inhibition of ENT1. We incubated primary mouse hepatocytes with AICAR and metformin in the presence of the selective ENT1 inhibitor NBMPR ( Figure 4A ). This compound was sufficient to promote HGP alone, but completely blocked the action of AICAR on HGP ( Figure 4B ). The effect of metformin on AMPK and ACC phosphorylation was not modified by the presence of NBMPR ( Figure 4B,D) , whereas AICAR failed to alter AMPK or ACC phosphorylation in the presence of NBMPR ( Figure 4B,E,F) . These data strongly suggest that AICAR uptake into mouse hepatocytes is mediated by ENT1. To confirm that 8CPT-cAMP and 8CPT-2MeO-cAMP inhibit ENT1 in hepatocytes, we performed an uptake assay, using radiolabelled uridine as a tracer and a known ENT1 substrate to measure ENT1 activity in the absence and presence of NBMPR, 8CPT-cAMP, 8CPT-2MeO-cAMP, db-cAMP and glucagon. We found that 3 Huridine uptake was inhibited by NBMPR, 8CPT-cAMP and 8CPT-2MeO-cAMP but was not inhibited by db-cAMP or glucagon ( Figure 5 ). To reinforce these findings, we carried out LC-MS analysis of AICAR depletion from cellular medium. A scan of cell culture medium without AICAR is presented online ( Figure S2A ). On the same column, AICAR ran as a single peak at 2.91 minutes ( Figure S2B-S2D ).
We then established that addition of AICAR alone to the medium was stable up to 24 hours, with LC-MS traces superimposable (0 vs 360 minutes) ( Figure 5B), indicating that AICAR is not degraded over this time-period. In contrast, in media harvested from cells treated with AICAR, we observed AICAR loss from the medium ( Figure 5C ), which was blocked by NBMPR, 8CPT-cAMP and 2MeO-8CPT-cAMP ( Figure 5D ). 
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FIGURE 4 AICAR uptake into hepatocytes is mediated by equilibrative nucleoside transporter 1 (ENT1). A, HGP was measured after incubation for 8 hours with the selective ENT1 inhibitor NBMPR (100 nM) AE metformin (250 μM) or AICAR (250 μM). The amount of glucose produced was normalized to protein content and expressed as % control. B, Representative immunoblots measuring pThr172 AMPK and pSer79 ACC by metformin (250 μM) or AICAR (250 μM) AE NBMPR (100 nM). C-F, Densitometric analysis of ACC (C, E) and AMPK (D, F) phosphorylation, expressed as fold change of control. Data are taken from 4 separate experiments and shown as mean AE SEM, (*P < 0.05; **P < 0.01; ***P < 0.001 in pairwise comparisons). Abbreviations: Con, control; ns, not significant mechanism of 8CPT-cAMP/8CPT-adenosine dependent inhibition of ENT1 is uncertain but is probably related to the fact that 8CPT-cAMP is more lipophilic than cAMP by one order of magnitude. 28 This significant off-target effect of 8CPT-modified cAMP analogues suggests that caution should be exercised in future studies using 8CPT-cAMP to stimulate HGP. In the current study, however, we
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exploited this action of 8CPT-modified cAMP analogues to compare hepatic actions of AICAR and metformin.
We excluded a role for PKA/Epac activation in the blocking effect of 8CPT-modified cAMP analogues on AICAR-dependent suppression of HGP, on the assumption that cAMP does not affect the inhibitory effect of AICAR on HGP, when raised by the physiological inducer of cAMP, glucagon, and by the adenylate cyclase activator, forskolin.
Importantly, it has been reported previously that 8CPT-modified cAMP analogues inhibit nucleoside transporters, 23 which are divided into two different families: constitutive nucleoside transporters (CNT) (SLC28), of which there are three members (CNT1-3) or equilibrative nucleoside transporters (ENT) (SLC29), of which there are four members (ENT1-4). 29 These nucleoside transporters are responsible for transporting nucleosides such as adenosine and uridine into the cell.
In the brain, AICAR elevates adenosine levels, thought to be mediated by competition for or blockade of ENT1. 27 Therefore, we used a highly selective inhibitor of ENT1, NBMPR, to demonstrate that ENT1
inhibition is sufficient to block the effect of AICAR on HGP and AMPK signalling. Molecular docking data are unavailable for 8CPT-cAMP analogues docking to ENT1 but in contrast, robust 3D-Quantitative
Structure-Activity Relationship analysis is available for NBMPR/ENT1
interaction. [30] [31] [32] NBMPR did not alter the effects of metformin on AMPK and HGP. At the nanomolar concentrations used in the current study, NBMPR is highly specific for ENT1 which has a unique highaffinity binding site for this drug. 24 In recombinant systems, NBMPR inhibits ENT1 7000-fold more potently than ENT2, 24, 33 and it does not inhibit CNT3. 34 In rat hepatic membrane preparations, NBMPR is without effect on Na + -dependent (concentrative) adenosine transport activity. 35 To further validate that AICAR was taken up via ENT1, we used 3 H-uridine as a tracer. We confirmed that 8CPT-cAMP analogues and NBMPR inhibit uridine uptake into hepatocytes. We then cross-validated with LC-MS, demonstrating that AICAR is depleted from media harvested from AICAR-treated hepatocytes, which was prevented by NBMPR and 8CPT-modified cAMP analogues. Using an additional control, we did not observe any major degradation products of AICAR in the medium, indicating that AICAR depletion is most likely the result of cellular uptake. The difference between AICAR and metformin sensitivity to NBMPR is consistent with metformin being taken into the cell via OCT transporters, as reported previously. 19, 20 Our findings may explain previous observations that required the use of very high (2 mM) concentrations of AICAR to inhibit 8CPT-cAMPinduced HGP. 11 Taken together, our data suggest that 8CPT-modified cAMP analogues and NBMPR inhibit ENT1 to block AICAR entry, preventing AICAR-mediated inhibition of HGP and activation of AMPK ( Figure 5E ). Direct ENT1 inhibition with NBMPR which, in other tissues, raises extracellular adenosine levels, 36, 37 was sufficient to increase HGP ( Figure 5E ). This is probably mediated indirectly by activation of adenosine receptor-mediated glycogenolysis or gluconeogenesis. 38 In addition to adenosine, ENT1 also transports uridine, which promotes feeding via activation of hypothalamic uridine diphosphate receptor, P2Y6, 39 and which may also contribute AMPK-independent effects of AICAR on metabolism. Several clinically used drugs inhibit ENT1 as a secondary mode of action, including rosuvastatin 40 and dipyridamole. 41 Interestingly, rosuvastatin increases HbA1c in individuals with and without diabetes, 42 and dipyridamole increases glycaemia in mice. 43 Taken together, these data suggest that therapeutic alterations in purine salvage may produce a clinically significant alteration in HGP via modulation of adenosine receptors.
In summary, we report for the first time that suppression of ENT1 induces HGP. ENT1 inhibition also impedes uptake and the effects of AICAR, but not of metformin, on HGP. These data delineate the differing pathways by which AICAR and metformin regulate HGP, and more study is required to determine whether exploitation of these pathways can be used for further therapeutic intervention in diabetes.
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